Philippines - English - FDA (Food And Drug Administration)

n/a; importer: glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2023 strain - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - co-amoxiclav - powder for injection (i.v) - 500 mg/100 mg

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - co-amoxiclav - powder for injection (iv) - 1 g/200 mg

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines inc. - co-amoxiclav - powder for suspension (infant drops) - 50mg + 12.5mg / ml

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline consumer healthcare philippines, inc.; distributor: philusa corporation - co-amoxiclav - powder for suspension - 400mg/57mg per 5ml

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - co-amoxiclav - powder for injection (i.v) - 500mg / 100mg

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) northern hemisphere 2016/2017 strain (see formulation on reverse side) - suspension for injection (i.m.) - refer to generic name

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2016 (see formulation on reverse side) - suspension for injection (im/sc) - refer to generic name

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: glaxosmithkline philippines, inc.; distributor: n/a - co-amoxiclav - powder for suspension - 228.5 mg per 5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, powder for - excipient ingredients: polysorbate 80; water for injections; dibasic sodium phosphate heptahydrate; sucrose - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).